Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Table 2 Patients’ characteristics at virological failure

Patient ID	Previous resistance mutations	Nadir CD4+ (cells/μL)	HIV-RNA zenith (copies/mL)	CD4 + (cells/μL) at baseline	HIV-RNA at baseline	3rd drug	CD4 + (cells/μL) at failure	HIV-RNA (copies/mL) at failure	History of NRTI failure	History of NNRTI failure	History of PI failure	NRTI mutations	NNRTI mutations	PI mutations	InSTI mutations
1412	N/A	258	500.000	675	Undetectable	RPV	691	69	Yes	No	Yes	None	None	None	None
1428	N/A	200	1.400.000	700	Residual viremia	RAL	356	11.236	Yes	Yes	Yes	M41 L, M184 V, L210 W, T215Y	K103 N, V108I	None	N155H
2718	N/A	245	350.000	922	Undetectable	RPV	660	27.823	No	No	No	M41 L, K65R, D67N, M184 V	Y181V	M46I	None
4418	N/A	229	751.000	674	Residual viremia	RPV	578	4.737	No	No	No	A62V, K65R, M184 V	V106I, E138K, H221Y	None	N/A
5443	N/A	113	1.978.100	694	Residual viremia	RPV	648	367	No	No	No	N/A	N/A	N/A	N/A
5799	N/A	324	70.000	653	Residual viremia	RAL	594	138	Yes	No	No	N/A	N/A	N/A	None
5967	N/A	182	78,674	1166	Undetectable	RPV	1083	326	No	No	No	D67N, K70R, M184 V, T215I, K219E	L100I, K103 N, V179 T	None	None
6264	N/A	374	570	904	Residual viremia	RAL	697	216	No	No	No	N/A	N/A	N/A	N/A
7165	None	488	1.492.000	995	Undetectable	RPV	1224	181	No	No	No	N/A	N/A	N/A	N/A
8270	None	108	374.400	444	Undetectable	RPV	598	89	Yes	No	Yes	N/A	N/A	N/A	N/A
9037	None	283	46.291	921	Undetectable	RPV	1067	104	No	No	No	N/A	N/A	N/A	N/A
9827	N/A	95	279	113	Residual viremia	EVG/COBI	174	52	No	No	No	N/A	N/A	N/A	None

EVG/COBI Elvitegravir/cobicistat, InSTI Integrase strand transfer inhibitor, N/A Not available, NNRTI Non-nucleoside reverse transcriptase inhibitor, NRTIs Nucleoside reverse transcriptase inhibitors, PI Protease inhibitor, RAL Raltegravir, RPV Rilpivirine

ISSN: 1471-2334